MacTel: Navigating A New Treatment Era
Posted on February 22, 2026 by Miriah Teeter, M.D. in Past CE/CME Presentations
Presented by Miriah Teeter, M.D., Retina Specialist at Colorado Retina Associates
CRA's 2026 Mile High Masters of Retina meeting
This pre-recorded talk, provides primary eye care providers with an overview of Macular Telangiectasia and its complex pathophysiology, highlighting the first FDA-approved treatment option, ENCELTO, and its role in contemporary disease management.
CLINICAL PEARLS:
MacTel is a genetic neuroglial degenerative disease resulting in progressive bilateral maculopathy in middle aged adults
Encelto is the first proven MacTel treatment to help preserve macular function over time
Early detection and referral is key to providing maximal treatment benefit
Ongoing research into MacTel holds promise for future treatment options
